Caring for patients with heart failure at home
With help from the Prisma Health team, more than 400 heart failure patients have improved their quality of life using CardioMEMS™, a wireless device that allows patients to monitor their pulmonary artery pressure from the comfort of home. Prisma Health is the leading implanter of CardioMEMS™ in the nation.
CardioMEMS™ utilizes a small, wireless sensor that is implanted in the pulmonary artery using a minimally invasive procedure. The sensor, designed to last a lifetime, is a sealed capsule that uses microelectromechanical systems (MEMS) technology, ensuring stability and energy efficiency in measurements.
A portable external unit with a customized pillow allows patients to log pulmonary artery (PA) pressure readings from their homes across South Carolina and transmit the information to the Prisma Health team.
CardioMEMS™ has helped physicians successfully keep Heart failure patients out of the hospital by providing more proactive management of the patient’s condition. Not only does Cardio MEMS™ offer physicians real-time notification of patient changes and access to secure data for management, it also empowers patients to engage and improve their cardiovascular health.
CardioMEMS™ is effective in both types of heart failure – heart failure with preserved ejection fraction (diastolic heart failure) and reduced ejection fraction (systolic heart failure).
In multiple clinical studies of heart failure patients**, the CardioMEMS™ HF System led to a:
- Significant improvement in quality of life
- Increase in 6-minute walk distance
- Reduction in heart failure hospitalizations
Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:
- Fluid volumes that are hard to know or manage
- Challenging physical assessment
- Is a patient with HFpEF or HFrEF
- Compliant with heart failure medical care
- Would benefit from remote monitoring if they live far from a clinic
Consider referring a patient for evaluation with the heart failure team at Prisma Health.
Patrick J. McCann, MD
Rebecca S. Napier, MD
Eric L. Bonno, MD
Jason L. Guichard, MD, PhD
Dev G. Vaz, MD
**In the CHAMPION clinical trial (CardioMEMS Heart Sensor Allows Monitoring of Pressures to Improve Outcomes in NYHA Class III Heart Failure Patients),patients with moderate (NYHA Class III) heart failure for at least three months, irrespective of left ventricular ejection fraction, and a heart failure hospitalization within the past 12 months were included in the study.
Abraham, W. T., Stevenson, L. W., Bourge, R. C., Lindenfeld, J. A., Bauman, J. G., & Adamson, P. B., for the CHAMPION Trial Study Group. (2016). Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet, 387 (10017), 453-461.
Alam, A., Jermyn, R., Joseph, M., Patel, S., Jorde, U., & Saeed, O. (2016, April). Improved quality of life scores and exercise capacity with remote pulmonary pressure monitoring in patients with chronic heart failure. Presentation 903-06. American College of Cardiology 2016 Scientific Sessions, Chicago.